SCHEMBL965984

SCHEMBL965984

COC(=O)NC1CCCNC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.55
OPRK1 P41145 1/20 0.55
SLC6A1 P30531 2/20 0.41
SLC6A11 P48066 1/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A13 Q9NSD5 1/20 0.41
PBK Q96KB5 4/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
CYP2D6 P10635 1/20 0.40
EPHX1 P07099 2/20 0.39
CHRNA1 P02708 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHEK1 O14757 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27714012 1.00 MAPK1 (0.55) MAPK1OPRK1SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL2899466 0.98 MAPK1 (0.54) MAPK1OPRK1SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL17560419 0.98 MAPK1 (0.54) MAPK1OPRK1SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL17560443 0.98 MAPK1 (0.54) MAPK1OPRK1SLC6A1SLC6A11TSHR
Trifluoroacetic Acid SCHEMBL30656190 0.89 MAPK1 (0.47) MAPK1OPRK1SLC6A1SLC6A11TSHR
SCHEMBL14222420 0.89 EPHX1 (0.47) MAPK1OPRK1SLC6A1SLC6A11TSHR
SCHEMBL1778461 0.89 EPHX1 (0.47) MAPK1OPRK1SLC6A1SLC6A11TSHR
SCHEMBL5320954 0.89 EPHX1 (0.47) MAPK1OPRK1SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL17560406 0.87 EPHX1 (0.45) MAPK1OPRK1SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL17560408 0.87 EPHX1 (0.45) MAPK1OPRK1SLC6A1SLC6A11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 WO disclosed
WO-2023018812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2023-02-16 WO disclosed
CN-113365996-A Imidazopyridine derivative compounds and uses thereof 韩美药品株式会社 2021-09-07 CN disclosed
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
CN-105399698-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2018-08-10 CN disclosed
CN-104334546-B Novel ring-substituted N-pyridyl amides as kinase inhibitors 诺华股份有限公司 2017-05-03 CN disclosed
CN-102448958-B Pyrimidyl and 1,3,5-triazines base benzimidazole sulfonamides and its purposes in cancer therapy VETDC, INC. (US) 2015-10-21 CN disclosed
EP-2471775-A1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO., LTD. (JP) 2012-07-04 EP disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
CN-101068794-A Quinazolines useful as modulators of ion channels VERTEX PHARMA (US) 2007-11-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 MAPK1 526/4885OPRK1 68/4885SLC6A1 3378/4885
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L MAPK1 3124/4885OPRK1 3123/4885SLC6A1 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.